AnalystsGavin Clark-Gartner
Gavin Clark-Gartner's Stock Forecasts

Analyst Ranking
Bottom 5%
#4766 out of 4986 analysts
Average Return
-11.9%
Win Rate
41%11 out of 27
Risk vs Reward
Poor
Good

Gavin Clark-Gartner's 5 best and worst ratings

Name / TickerGain/LossEntry PriceExit PricePeriodRating
Argenx SeARGX
+76.16%$354.13$623.82
2023-12-21 -
2024-12-20
Buy
Mirum Pharmaceuticals IncMIRM
+50.04%$39.87$59.82
2024-08-08 -
2025-08-07
Buy
C4 Therapeutics IncCCCC
+48.96%$3.35$4.99
2023-05-30 -
2024-05-29
Buy
Mirum Pharmaceuticals IncMIRM
+37.60%$28.91$39.78
2023-10-17 -
2024-10-16
Buy
Mind Medicine IncMNMD
+26.38%$7.43$9.39
2025-01-28 -
2025-08-19
Buy

Gavin Clark-Gartner Analyst Color

Get additional color on Gavin Clark-Gartner's coverage of popular stocks

Gavin Clark-Gartner's Stock Coverage

Name / TickerNo. RatingsRatingPrice TargetUpside/DownsideActionDate
Mirum Pharmaceuticals IncMIRM
3Buy$89.00+36.59%Maintains
12 days ago
Jasper Therapeutics IncJSPR
3Buy$20.00+601.75%Maintains
a month ago
Proqr Therapeutics NvPRQR
1Buy$5.00+146.31%Initiates Coverage On
4 months ago
Abbvie IncABBV
3Buy$205.00-0.58%Maintains
4 months ago
Mind Medicine IncMNMD
1Buy$23.00+144.94%Initiates Coverage On
7 months ago
Cabaletta Bio IncCABA
2Hold$6.00+270.37%Downgrades
8 months ago
Argenx SeARGX
4Buy$706.00+7.48%Maintains
9 months ago
Sarepta Therapeutics IncSRPT
9Buy$170.00+742.42%Maintains
9 months ago
Foghorn Therapeutics IncFHTX
1Buy$20.00N/AInitiates Coverage On
a year ago
Krystal Biotech IncKRYS
1Buy$206.00N/AMaintains
a year ago
Aclaris Therapeutics IncACRS
1Buy$22.00N/AInitiates Coverage On
2 years ago
C4 Therapeutics IncCCCC
1Buy$10.00N/AMaintains
2 years ago
Inhibrx IncINBX1
1Buy$60.00N/AMaintains
3 years ago
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.